Our Leadership

Message from the CEO

Cary Gunn

Cary Gunn, PhD

President, CEO, and Founder

“Genalyte is transforming the doctor-patient relationship by providing rapid diagnostic testing right in the doctor’s office. Our technology delivers results to physicians in minutes from just a single drop of blood, yielding better outcomes for the patient, empowering doctors to be more effective, and creating a more efficient healthcare system.”

Dr. Gunn currently holds 81 issued US patents, with more in process.  In 2003, he was recognized by MIT Technology Review as a Top Young Innovator. In 2008, he received the Optical Society of America Adolph Lomb medal and the Berthold-Leibinger Foundation Innovation Prize. Dr. Gunn also co-founded Luxtera where he was responsible for technology development and served as CTO until 2007.

Dr. Gunn received his PhD from Caltech in Electrical Engineering. Before that Dr. Gunn was an officer in the US Air Force, responsible for launching GPS satellites. He is a graduate of the US Air Force Academy.

The Executive Team

Martin Gleeson, PhD


Over 30 years experience in research, development, and launch of innovative products.
Founding director of ZyGem Corp and directed R&D at Invitrogen.
PhD in Genetics from the University of Sheffield, England.
Holds more than 30 pending and issued patents and has written more than 25 publications.

Ted Holtaway


Over 30 years experience in manufacturing quality and operations spanning startup.
Multi-national businesses EVP.
Worldwide Operations for Cymer, global manufacturing, supply chain, product development and IT.
Grew Brooktree manufacturing from start up thru IPO, managed ops, reliability and quality.

Brett Brown

VP, Finance

Over 15 years experience in business development and establishing strategic financial partnerships.
Broad portfolio of capital development expertise.
Vice President of Finance for Elevated Resources Inc. and Director of Finance for Luxtera Inc.
MBA from University of California, Irvine.

Rick Hockett, MD


Over 30 years of experience in applying biomarkers to clinical medicine.
As a Board Certified Clinical Pathologist, Dr. Hockett’s specialties include molecular diagnostics, clinical application of technology and biomarker strategies.
Has served as Chief Medical Officer with Biodesix, CombiMatrix, and Affymetrix. With a proven track record in developing the clinical regulatory strategies for diagnostics, and FDA, CLIA and EMEA interactions.
M.D from the University of Minnesota with a residency in Clinical Pathology at Washington University, St. Louis.

Aaron Hanson, PhD

VP, Technology Transfer and Consumables Manufacturing

Over 18 years experience in RUO and IVD chemical and biologic manufacturing space.
With names including Sequenom, Invitrogen, Illumina, Synthetic Genomics and Alere.
Proven domestic and international track record in scaling technologies, improving productivity and performing product and portfolio technology transfers.
Ph. D. in Pharmaceutical Science, Medicinal Chemistry from the University of Nebraska.
Developed and patented surface chemistry processes.

Sasi Mudumba, PhD

VP, Assay Development 

Over 22 years of expertise in research, product development and commercialization.
Developed and implemented strategies for FDA, EU and Health Canada reviews resulting in regulatory approvals.
Proven track record in developing and obtaining regulatory approval for multiplexed IVD assays from FDA, EU and Health Canada.
Ph.D in Bio-Technology from Jawaharlal Nehru Technological University.


Board of Directors

Brad Webb

Member, Board of Directors

Brad Webb, PhD has been a Venture Partner at Claremont Creek Ventures since 2005.
Focusing on life science investing – deal sourcing, due diligence, and Board of Director responsibilities with portfolio companies.
In addition to activities with Claremont Creek, Brad is a member of Tech Coast Angels, a Southern California based Angel investor group, is active with UC Santa Barbara technology programs, and consults with startups in medical and life sciences technology areas.
Brad received a B. S. in Chemistry from UC Davis, and a Ph.D. in Biochemistry and Molecular Biology at UC  Santa Barbara.

Joe Markee

Member, Board of Directors

Joe Markee is currently a Managing Director at Express Ventures.
He brings extensive experience in early stage company formation, capital raising, corporate management, and public and private corporate governance.
Joe’s startup experience encompasses Primary Access as a founder and senior manager, Copper Mountain Networks as founding CEO, CTO and Chairman, and Figure 8 Wireless as CEO.
Joe serves on the boards of Biomatrica, Genalyte, Certona, Maintenance Net, EBand Communications, Rockco and Filmetrics.

Vijit Sabnis

Member, Board of Directors

Vijit Sabnis is a venture partner at Khosla Ventures, where he focuses on emerging physical and life science technologies.
Prior to Khosla Ventures, Vijit was a co-founder and the CEO of Solar Junction, a manufacturer of high-efficiency multi-junction solar cells.
Vijit holds a bachelor’s of science degree in electrical engineering and computer science with highest honors from the University of California, Berkeley. He also holds a master’s of science degree and Ph.D. in electrical engineering from Stanford University, where he received a National Science Foundation fellowship and a Stanford electrical engineering department fellowship.

Frank Litvak

Member, Board of Directors

Frank Litvak, MD has been a member of the Board of Directors at Genalyte since March 2012.
Dr. Litvack served as Chairman (from 2002) and CEO (from 2003) of Conor MedSystems, Inc., a publicly-held company focused on the development of vascular drug delivery systems, until its acquisition by Johnson & Johnson in February 2007.
From 2000 to 2005, Dr. Litvack was Chairman of Savacor, Inc., a medical device company that was acquired by St. Jude Medical, Inc. in late 2005.
Since 2000, Dr. Litvack has been a Professor of Medicine at University of California, Los Angeles.
Dr. Litvack has been an attending cardiologist at Cedars-Sinai Medical Center since 1985 and co-directed the Cardiovascular Intervention Center at Cedars-Sinai Medical Center from 1986 to 2000.
Currently serves as a director of several privately-held corporations. Dr. Litvack holds an M.D. from McGill University.

William A. Hagstrom

Member, Board of Directors

William A. Hagstrom is the founder and CEO of Octave Bioscience and the former CEO of Crescendo Bioscience
Mr. Hagstrom brings more than three decades of executive and board-level experience in the healthcare and diagnostic sectors to Genalyte. He is currently the founder and CEO of Octave Bioscience, an early-stage diagnostics company focused on neurodegenerative diseases.
At Crescendo, which focused on diagnostics related to autoimmune and inflammatory diseases, Mr. Hagstrom secured financing and led the development of the company’s commercial strategy and product pipeline before it was acquired by Myriad Genetics in 2014.
Prior to joining Crescendo, Mr. Hagstrom served as president of Alpha BioPartners, a strategic consulting firm specializing in early-stage biotechnology companies. While there, he co-founded Biolytx Pharmaceuticals and Altheus Therapeutics, and served as interim CEO of Selexys Pharmaceuticals and Inoveon. Mr. Hagstrom also served as the Chairman and CEO of specialty diagnostics firm UroCor, as well as held executive positions at multinational healthcare firms Becton Dickinson, American Hospital Supply and Baxter International.
Mr. Hagstrom holds B.S. in Business Management from Bob Jones University.
A blog about Wordpress design, development , Software and inspiration http://themesharebd.blogspot.com